Lucy Godley to Myeloid Cells
This is a "connection" page, showing publications Lucy Godley has written about Myeloid Cells.
Connection Strength
0.741
-
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
Score: 0.370
-
Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017 Aug; 106(2):189-195.
Score: 0.150
-
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011 Jul 12; 20(1):11-24.
Score: 0.100
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14; 18(6):553-67.
Score: 0.096
-
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011 Jul 12; 20(1):25-38.
Score: 0.025